All patients diagnosed with early-onset colorectal cancer (EOCRC) should undergo germline multigene panel testing, as recommended by current National Comprehensive Cancer Network guidelines, to inform ...
WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...
Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) “Petosemtamab’s unique mechanism of ...
The diagnosis and treatment of colon cancer have evolved considerably, with early detection and accurate staging underpinning improved patient outcomes. In recent years, multidisciplinary approaches ...
CHICAGO -- The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients who received immunotherapy in addition to adjuvant chemotherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results